| Pharmacokinetics, Safety and Tolerability of Chiglitazar, A Novel Peroxisome Proliferator-Activated Receptor (PPAR) Pan-Agonist, in HealthyChinese Volunteers:A Phase I Study | |
| Xu, Hong-Rong; Zhang, Jin-Wen; Chen, Wei-li; Ning, Zhi-Qiang; Li, Xue-Ning | |
| 刊名 | CLINICAL DRUG INVESTIGATION
 |
| 2019 | |
| 卷号 | 39期号:6 |
| ISSN号 | 1173-2563 |
| URL标识 | 查看原文 |
| 语种 | 英语 |
| 内容类型 | 期刊论文 |
| URI标识 | http://www.corc.org.cn/handle/1471x/3594847 |
| 专题 | 复旦大学上海医学院 |
| 推荐引用方式 GB/T 7714 | Xu, Hong-Rong,Zhang, Jin-Wen,Chen, Wei-li,et al. Pharmacokinetics, Safety and Tolerability of Chiglitazar, A Novel Peroxisome Proliferator-Activated Receptor (PPAR) Pan-Agonist, in HealthyChinese Volunteers:A Phase I Study[J]. CLINICAL DRUG INVESTIGATION,2019,39(6). |
| APA | Xu, Hong-Rong,Zhang, Jin-Wen,Chen, Wei-li,Ning, Zhi-Qiang,&Li, Xue-Ning.(2019).Pharmacokinetics, Safety and Tolerability of Chiglitazar, A Novel Peroxisome Proliferator-Activated Receptor (PPAR) Pan-Agonist, in HealthyChinese Volunteers:A Phase I Study.CLINICAL DRUG INVESTIGATION,39(6). |
| MLA | Xu, Hong-Rong,et al."Pharmacokinetics, Safety and Tolerability of Chiglitazar, A Novel Peroxisome Proliferator-Activated Receptor (PPAR) Pan-Agonist, in HealthyChinese Volunteers:A Phase I Study".CLINICAL DRUG INVESTIGATION 39.6(2019). |
| 个性服务 |
| 查看访问统计 |
| 相关权益政策 |
| 暂无数据 |
| 收藏/分享 |
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。
修改评论